Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities
Article Abstract:
Recent research results have linked the development of malignant disease, such as certain leukemias, to chromosomal abnormalities. It is possible that one of these disorders is B-cell chronic lymphocytic leukemia (CLL), a malignant condition in which excess B cells (a type of white blood cell) are produced. However, problems connected with stimulation of B cells have slowed research. To address the issue, five European medical centers began a collaborative study to evaluate the chromosomes of people with B-cell CLL. The first report is presented, in which 433 patients were studied. Abnormalities were found on chromosome 12 in 67 patients; on chromosome 13 in 51 patients; and on chromosome 14 in 41 patients. Individuals with chromosomal abnormalities had poorer survival (7.7 years) than those with normal chromosomes (more than 15 years). Survival was poorest for those with abnormalities on chromosome 14. For those with abnormalities on chromosome 13, survival rates were not dramatically different from patients with normal chromosomes. Thus, chromosomal analysis appears to be a useful prognostic aid in B-cell CLL. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1990
User Contributions:
Comment about this article or add new information about this topic:
Chronic lymphocytic leukemia
Article Abstract:
Chronic lymphocytic leukemia (CLL) involves excessive multiplication of B lymphocytes and occurs predominantly in people over the age of 50. Although genetic factors may be involved, the exact cause of CLL is unknown. Diagnosis can be made based on high levels of white blood cells, immunologic classification of lymphocytes, and their presence in bone marrow. Symptoms may include changes in lymph glands, fatigue, and loss of weight. Survival varies with a median of approximately nine years. CLL should be treated if symptoms are severe, lymph organs are compressing other organs, lymphocyte counts are increasing quickly, or bone marrow is full of lymphocytes. Therapies include chlorambucil, corticosteroids, purine analogues, interferon, low doses of immune globulin, and antibiotic treatment of opportunistic infections. Bone marrow transplantation may be effective but is still viewed as experimental. Experimental treatments should be considered in young patients with severe disease.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
When and how to treat chronic lymphocytic leukemia
Article Abstract:
Two doctors present their recommendations for treating patients with chronic lymphocytic leukemia. Treatment will vary depending on the patient's age, overall health, co-existing disease, and tumor stage.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Mandatory Reporting of Diseases and Conditions by Health Care Professionals and Laboratories. Use of Medical Care, Police Assistance, and Restraining Orders by Women Reporting Intimate Partner Violence--Massachusetts, 1996-1997
- Abstracts: Trends in evolution of specialty choice: comparison of US medical school graduates in 1983 and 1987
- Abstracts: A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Measles vaccines: a positive step toward eradicating a negative strand
- Abstracts: A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase. Kourilsky to reform the Pasteur Institute
- Abstracts: Import of host delta-aminolevulinate dehydratase into the malaraial parasite: identification of a new drug target